ABBV 951 is filed in Japan to treat Parkinson's disease. AbbVie
AbbVie filed a new drug application (NDA) in Japan for its investigational advanced Parkinson’s disease treatment ABBV 951 (foslevodopa + foscarbidopa), which contains the prodrugs of levodopa and carbidopa. This is a continuous subcutaneous injectable agent developed by improving the molecular structure of levodopa and carbidopa.
Patients with advanced Parkinson’s disease undergo surgery to supplement dopamine through gastrostoma, Since the administration of ABBV 951 does not require surgery, AbbVie expects that this drug will reduce the burden on patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins